{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-166987","form_type":"8-K","ticker":"ALGS","cik":"0001799448","company_name":"Aligos Therapeutics, Inc.","filed_at":"2026-04-21T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.926691+00:00","generated_at":"2026-05-15T05:08:50.320524+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Aligos licenses pevifoscorvir sodium to Amoytop for China/Taiwan/HK/Macau; upfront $25M, milestones up to $420M","bullets":["Exclusive license to develop and commercialize pevifoscorvir sodium for HBV and HBV/HDV in mainland China, Taiwan, Hong Kong, and Macau.","Upfront cash payment of $25 million from Amoytop; eligible for up to $420 million in development, regulatory, and commercial milestones.","Tiered high single-digit royalties on net sales in the Territory.","Amoytop responsible for all development, regulatory, manufacturing, and commercialization costs in the Territory.","Effectiveness conditional on Amoytop shareholder approval within 45 days of signing."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-166987","json":"https://secwatch.observer/filing/0001193125-26-166987.json","markdown":"https://secwatch.observer/filing/0001193125-26-166987.md","text":"https://secwatch.observer/filing/0001193125-26-166987.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1799448/000119312526166987/0001193125-26-166987-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1799448/000119312526166987/d50981d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T05:08:50.320524+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"77dc774fbcde45de3769f9272c22c5a7a13ca9c6","claim":"Aligos Therapeutics, Inc. entered into License Agreement with Xiamen Amoytop Biotech Co., Ltd. valued at $25 million (effective 2026-04-16).","evidence_excerpt":"On April 16, 2026, Aligos Therapeutics, Inc. (the “Company”) entered into a License Agreement (the “License Agreement”) with Xiamen Amoytop Biotech Co., Ltd. (“Amoytop”), pursuant to which the Company grants to Amoytop an exclusive, non-transferable, royalty-bearing license, under certain Company-controlled intellectual property, to manufacture, develop and commercialize the Company’s investigational compound pevifoscorvir sodium in its current dosage form, formulation, and mode of administration (the “Licensed Product”) in the field of the treatment, prevention or palliation of Hepatitis B virus infection in humans, or Hepatitis B virus and Hepatitis D virus co-infection in humans (the “Field”), in the territory of mainland China, Taiwan, and the Special Administrative Regions of Hong Kong and Macau (the “Territory”). Amoytop has the right to have the Licensed Product made in the Territory by manufacturers meeting certain criteria, and to sublicense its rights, subject to certain rest","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1799448/000119312526166987/0001193125-26-166987-index.htm","confidence":0.9}],"comparable_filings":[{"accession":"0001193125-26-252560","ticker":"CURB","company_name":"Curbline Properties Corp.","filed_at":"2026-06-02T12:07:02+00:00","headline":"Curbline Properties enters up to $400M ATM equity offering; prior program terminated","event_type":"other_material","sec_items":["1.01","9.01"],"materiality_score":0.55,"calibrated_materiality_score":0.55,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-252560","json":"https://secwatch.observer/filing/0001193125-26-252560.json","markdown":"https://secwatch.observer/filing/0001193125-26-252560.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2027317/000119312526252560/0001193125-26-252560-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2027317/000119312526252560/d111894d8k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On April 16, 2026, Aligos Therapeutics, Inc. (the “Company”) entered into a License Agreement (the “License Agreement”) with Xiamen Amoytop Biotech Co., Ltd. (“Amoytop”), pursuant to which the Company grants to Amoytop an exclusive, non-transferable, royalty-bearing license, under certain Company-controlled intellectual property, to manufacture, develop and commercialize the Company’s investigational compound pevifoscorvir sodium in its current dosage form, formulation, and mode of administration (the “Licensed Product”) in the field of the treatment, prevention or palliation of Hepatitis B virus infection in humans, or Hepatitis B virus and Hepatitis D virus co-infection in humans (the “Field”), in the territory of mainland China, Taiwan, and the Special Administrative Regions of Hong Kong and Macau (the “Territory”). Amoytop has the right to have the Licensed Product made in the Territory by manufacturers meeting certain criteria, and to sublicense its rights, subject to certain rest","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1799448/000119312526166987/0001193125-26-166987-index.htm","comparable_excerpt":"On June 2, 2026, Curbline Properties Corp. (the “ Company ”) and Curbline Properties LP (the “ Operating Partnership ”) entered into an ATM Equity Offering Sales Agreement (the “ Equity Sales Agreement ”) with Jefferies LLC, BNY Mellon Capital Markets, LLC, BofA Securities, Inc., BTIG, LLC, Capital One Securities, Inc., Goldman Sachs & Co. LLC, KeyBanc Capital Markets Inc., Morgan Stanley & Co. LLC, Nomura Securities International, Inc., StoneX Financial Inc. and Wells Fargo Securities, LLC, as sales agents","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2027317/000119312526252560/0001193125-26-252560-index.htm"}},{"accession":"0001213900-26-063767","ticker":"BJDX","company_name":"Bluejay Diagnostics, Inc.","filed_at":"2026-06-02T10:30:41+00:00","headline":"Bluejay Diagnostics partners with Argonaut for US-based Symphony platform manufacturing","event_type":"other_material","sec_items":["1.01","7.01","9.01"],"materiality_score":0.55,"calibrated_materiality_score":0.55,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-063767","json":"https://secwatch.observer/filing/0001213900-26-063767.json","markdown":"https://secwatch.observer/filing/0001213900-26-063767.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1704287/000121390026063767/0001213900-26-063767-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1704287/000121390026063767/ea0293118-8k_bluejay.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On April 16, 2026, Aligos Therapeutics, Inc. (the “Company”) entered into a License Agreement (the “License Agreement”) with Xiamen Amoytop Biotech Co., Ltd. (“Amoytop”), pursuant to which the Company grants to Amoytop an exclusive, non-transferable, royalty-bearing license, under certain Company-controlled intellectual property, to manufacture, develop and commercialize the Company’s investigational compound pevifoscorvir sodium in its current dosage form, formulation, and mode of administration (the “Licensed Product”) in the field of the treatment, prevention or palliation of Hepatitis B virus infection in humans, or Hepatitis B virus and Hepatitis D virus co-infection in humans (the “Field”), in the territory of mainland China, Taiwan, and the Special Administrative Regions of Hong Kong and Macau (the “Territory”). Amoytop has the right to have the Licensed Product made in the Territory by manufacturers meeting certain criteria, and to sublicense its rights, subject to certain rest","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1799448/000119312526166987/0001193125-26-166987-index.htm","comparable_excerpt":"On May 27, 2026, Bluejay Diagnostics, Inc. (the “Company”) entered into an agreement and statement of work (together, the “Agreement”) with Argonaut Manufacturing Services c/o Argonaut, Inc. (“Argonaut”) regarding the provision by Argonaut to the Company of certain manufacturing services to support the Company’s SymphonyTM platform.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1704287/000121390026063767/0001213900-26-063767-index.htm"}},{"accession":"0001193125-26-252407","ticker":"FLY","company_name":"Firefly Aerospace Inc.","filed_at":"2026-06-02T10:21:08+00:00","headline":"Firefly Aerospace prices secondary offering of 12M shares at $48.00 per share","event_type":"other_material","sec_items":["1.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-252407","json":"https://secwatch.observer/filing/0001193125-26-252407.json","markdown":"https://secwatch.observer/filing/0001193125-26-252407.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1860160/000119312526252407/0001193125-26-252407-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1860160/000119312526252407/d156539d8k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On April 16, 2026, Aligos Therapeutics, Inc. (the “Company”) entered into a License Agreement (the “License Agreement”) with Xiamen Amoytop Biotech Co., Ltd. (“Amoytop”), pursuant to which the Company grants to Amoytop an exclusive, non-transferable, royalty-bearing license, under certain Company-controlled intellectual property, to manufacture, develop and commercialize the Company’s investigational compound pevifoscorvir sodium in its current dosage form, formulation, and mode of administration (the “Licensed Product”) in the field of the treatment, prevention or palliation of Hepatitis B virus infection in humans, or Hepatitis B virus and Hepatitis D virus co-infection in humans (the “Field”), in the territory of mainland China, Taiwan, and the Special Administrative Regions of Hong Kong and Macau (the “Territory”). Amoytop has the right to have the Licensed Product made in the Territory by manufacturers meeting certain criteria, and to sublicense its rights, subject to certain rest","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1799448/000119312526166987/0001193125-26-166987-index.htm","comparable_excerpt":"On May 28, 2026, in connection with the pricing of the Offering, the Company entered into an underwriting agreement (the \"Underwriting Agreement\") with Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, Jefferies LLC and Wells Fargo Securities, LLC, as representatives of the several underwriters listed on Schedule I thereto","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1860160/000119312526252407/0001193125-26-252407-index.htm"}},{"accession":"0001140361-26-023619","ticker":"GNK","company_name":"GENCO SHIPPING & TRADING LTD","filed_at":"2026-06-02T10:01:31+00:00","headline":"Genco Shipping amends shareholder rights plan, eliminates 'Acting in Concert' definition","event_type":"other_material","sec_items":["1.01","3.03","9.01"],"materiality_score":0.55,"calibrated_materiality_score":0.55,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-023619","json":"https://secwatch.observer/filing/0001140361-26-023619.json","markdown":"https://secwatch.observer/filing/0001140361-26-023619.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326200/000114036126023619/0001140361-26-023619-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326200/000114036126023619/ef20075333_8k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On April 16, 2026, Aligos Therapeutics, Inc. (the “Company”) entered into a License Agreement (the “License Agreement”) with Xiamen Amoytop Biotech Co., Ltd. (“Amoytop”), pursuant to which the Company grants to Amoytop an exclusive, non-transferable, royalty-bearing license, under certain Company-controlled intellectual property, to manufacture, develop and commercialize the Company’s investigational compound pevifoscorvir sodium in its current dosage form, formulation, and mode of administration (the “Licensed Product”) in the field of the treatment, prevention or palliation of Hepatitis B virus infection in humans, or Hepatitis B virus and Hepatitis D virus co-infection in humans (the “Field”), in the territory of mainland China, Taiwan, and the Special Administrative Regions of Hong Kong and Macau (the “Territory”). Amoytop has the right to have the Licensed Product made in the Territory by manufacturers meeting certain criteria, and to sublicense its rights, subject to certain rest","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1799448/000119312526166987/0001193125-26-166987-index.htm","comparable_excerpt":"On June 2, 2026, Genco Shipping & Trading Limited (the “ Company ”) entered into the Third Amendment to Shareholders Rights Agreement (the “ Third Amendment ”) to amend the Shareholder Rights Agreement, dated as of October 1, 2025 between the Company and Computershare Inc., as amended to date (the “ Rights Agreement ”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1326200/000114036126023619/0001140361-26-023619-index.htm"}},{"accession":"0001193125-26-251994","ticker":"TPST","company_name":"Tempest Therapeutics, Inc.","filed_at":"2026-06-01T23:13:20+00:00","headline":"Tempest Therapeutics enters warrant exercise inducement for ~$2M; issues new warrants to purchase 2.34M shares at $1.73","event_type":"other_material","sec_items":["1.01","3.02","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-251994","json":"https://secwatch.observer/filing/0001193125-26-251994.json","markdown":"https://secwatch.observer/filing/0001193125-26-251994.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1544227/000119312526251994/0001193125-26-251994-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1544227/000119312526251994/d105562d8k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On April 16, 2026, Aligos Therapeutics, Inc. (the “Company”) entered into a License Agreement (the “License Agreement”) with Xiamen Amoytop Biotech Co., Ltd. (“Amoytop”), pursuant to which the Company grants to Amoytop an exclusive, non-transferable, royalty-bearing license, under certain Company-controlled intellectual property, to manufacture, develop and commercialize the Company’s investigational compound pevifoscorvir sodium in its current dosage form, formulation, and mode of administration (the “Licensed Product”) in the field of the treatment, prevention or palliation of Hepatitis B virus infection in humans, or Hepatitis B virus and Hepatitis D virus co-infection in humans (the “Field”), in the territory of mainland China, Taiwan, and the Special Administrative Regions of Hong Kong and Macau (the “Territory”). Amoytop has the right to have the Licensed Product made in the Territory by manufacturers meeting certain criteria, and to sublicense its rights, subject to certain rest","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1799448/000119312526166987/0001193125-26-166987-index.htm","comparable_excerpt":"On May 28, 2026, Tempest Therapeutics, Inc., a Delaware corporation (the “ Company ”), entered into a warrant exercise and inducement offer letter agreement (the “ Inducement Letter ”) with a holder of certain existing warrants to purchase shares of the Company’s common stock","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1544227/000119312526251994/0001193125-26-251994-index.htm"}},{"accession":"0001193125-26-251791","ticker":"KRMN","company_name":"Karman Holdings Inc.","filed_at":"2026-06-01T21:28:29+00:00","headline":"Selling stockholders price upsized secondary offering of 14M shares at $61/share for ~$854M gross proceeds","event_type":"other_material","sec_items":["1.01","7.01","8.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-251791","json":"https://secwatch.observer/filing/0001193125-26-251791.json","markdown":"https://secwatch.observer/filing/0001193125-26-251791.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2040127/000119312526251791/0001193125-26-251791-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2040127/000119312526251791/d117104d8k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On April 16, 2026, Aligos Therapeutics, Inc. (the “Company”) entered into a License Agreement (the “License Agreement”) with Xiamen Amoytop Biotech Co., Ltd. (“Amoytop”), pursuant to which the Company grants to Amoytop an exclusive, non-transferable, royalty-bearing license, under certain Company-controlled intellectual property, to manufacture, develop and commercialize the Company’s investigational compound pevifoscorvir sodium in its current dosage form, formulation, and mode of administration (the “Licensed Product”) in the field of the treatment, prevention or palliation of Hepatitis B virus infection in humans, or Hepatitis B virus and Hepatitis D virus co-infection in humans (the “Field”), in the territory of mainland China, Taiwan, and the Special Administrative Regions of Hong Kong and Macau (the “Territory”). Amoytop has the right to have the Licensed Product made in the Territory by manufacturers meeting certain criteria, and to sublicense its rights, subject to certain rest","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1799448/000119312526166987/0001193125-26-166987-index.htm","comparable_excerpt":"On May 28, 2026, Karman Holdings Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with the persons named in Schedule II thereto (the “Selling Stockholders”) and Citigroup Global Markets Inc. and Evercore Group L.L.C., as the underwriters (the “Underwriters”), pursuant to which the Selling Stockholders agreed to sell 14,000,000 shares of common stock, par value $0.001 per share, of the Company (the “Common Stock”) at a public offering price of $61.00 per share (the “Offering Price”), less underwriting discounts and commissions (the “Offering”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2040127/000119312526251791/0001193125-26-251791-index.htm"}},{"accession":"0001193125-26-251789","ticker":"GIPR","company_name":"GENERATION INCOME PROPERTIES, INC.","filed_at":"2026-06-01T21:27:59+00:00","headline":"Generation Income Properties prices $5.0M public offering of 23.8M shares and warrants at $0.21/unit","event_type":"other_material","sec_items":["1.01","8.01","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-251789","json":"https://secwatch.observer/filing/0001193125-26-251789.json","markdown":"https://secwatch.observer/filing/0001193125-26-251789.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1651721/000119312526251789/0001193125-26-251789-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1651721/000119312526251789/gipr-20260528.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On April 16, 2026, Aligos Therapeutics, Inc. (the “Company”) entered into a License Agreement (the “License Agreement”) with Xiamen Amoytop Biotech Co., Ltd. (“Amoytop”), pursuant to which the Company grants to Amoytop an exclusive, non-transferable, royalty-bearing license, under certain Company-controlled intellectual property, to manufacture, develop and commercialize the Company’s investigational compound pevifoscorvir sodium in its current dosage form, formulation, and mode of administration (the “Licensed Product”) in the field of the treatment, prevention or palliation of Hepatitis B virus infection in humans, or Hepatitis B virus and Hepatitis D virus co-infection in humans (the “Field”), in the territory of mainland China, Taiwan, and the Special Administrative Regions of Hong Kong and Macau (the “Territory”). Amoytop has the right to have the Licensed Product made in the Territory by manufacturers meeting certain criteria, and to sublicense its rights, subject to certain rest","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1799448/000119312526166987/0001193125-26-166987-index.htm","comparable_excerpt":"In connection with the Offering, on May 28, 2026, the Company entered into a placement agency agreement (the “Placement Agency Agreement”) with Maxim Group LLC, as placement agent","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1651721/000119312526251789/0001193125-26-251789-index.htm"}},{"accession":"0001193125-26-251716","ticker":"SRG","company_name":"Seritage Growth Properties","filed_at":"2026-06-01T21:09:21+00:00","headline":"Seritage enters $50.8M option agreement to sell Dallas property to Arena Development","event_type":"other_material","sec_items":["1.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-251716","json":"https://secwatch.observer/filing/0001193125-26-251716.json","markdown":"https://secwatch.observer/filing/0001193125-26-251716.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1628063/000119312526251716/0001193125-26-251716-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1628063/000119312526251716/srg-20260601.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On April 16, 2026, Aligos Therapeutics, Inc. (the “Company”) entered into a License Agreement (the “License Agreement”) with Xiamen Amoytop Biotech Co., Ltd. (“Amoytop”), pursuant to which the Company grants to Amoytop an exclusive, non-transferable, royalty-bearing license, under certain Company-controlled intellectual property, to manufacture, develop and commercialize the Company’s investigational compound pevifoscorvir sodium in its current dosage form, formulation, and mode of administration (the “Licensed Product”) in the field of the treatment, prevention or palliation of Hepatitis B virus infection in humans, or Hepatitis B virus and Hepatitis D virus co-infection in humans (the “Field”), in the territory of mainland China, Taiwan, and the Special Administrative Regions of Hong Kong and Macau (the “Territory”). Amoytop has the right to have the Licensed Product made in the Territory by manufacturers meeting certain criteria, and to sublicense its rights, subject to certain rest","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1799448/000119312526166987/0001193125-26-166987-index.htm","comparable_excerpt":"On June 1, 2026 (the “Effective Date”), a subsidiary (the \"Seller\") of Seritage Growth Properties (the \"Company\") entered into an option purchase and sale agreement (the “PSA”) with Arena Development Intermediate, LLC, a Delaware limited liability company (the “Buyer”) for the sale of the Seller’s property located in Dallas, Texas (the \"Property\").","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1628063/000119312526251716/0001193125-26-251716-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}